Last reviewed · How we verify
liraglutide monotherapy
liraglutide monotherapy is a GLP-1 receptor agonist Small molecule drug developed by The Fourth Affiliated Hospital of Zhejiang University School of Medicine. It is currently FDA-approved for Type 2 diabetes mellitus monotherapy.
Liraglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to stimulate insulin secretion, suppress glucagon, and slow gastric emptying in response to elevated blood glucose.
Liraglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to stimulate insulin secretion, suppress glucagon, and slow gastric emptying in response to elevated blood glucose. Used for Type 2 diabetes mellitus monotherapy.
At a glance
| Generic name | liraglutide monotherapy |
|---|---|
| Sponsor | The Fourth Affiliated Hospital of Zhejiang University School of Medicine |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Liraglutide binds to and activates the GLP-1 receptor on pancreatic beta cells, enhancing glucose-dependent insulin secretion. It also inhibits glucagon secretion when blood glucose is elevated and delays gastric emptying, reducing postprandial glucose excursions. These combined effects improve glycemic control in type 2 diabetes.
Approved indications
- Type 2 diabetes mellitus monotherapy
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Headache
- Hypoglycemia
Key clinical trials
- RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients. (PHASE4)
- HbA1c Variability in Type II Diabetes (NA)
- Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes (PHASE3)
- Effect of GLP-1 on Angiogenesis (PHASE4)
- Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes (PHASE3)
- Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes (PHASE4)
- Trial for People With Established Type 2 Diabetes During Ramadan (PHASE4)
- Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- liraglutide monotherapy CI brief — competitive landscape report
- liraglutide monotherapy updates RSS · CI watch RSS
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine portfolio CI
Frequently asked questions about liraglutide monotherapy
What is liraglutide monotherapy?
How does liraglutide monotherapy work?
What is liraglutide monotherapy used for?
Who makes liraglutide monotherapy?
What drug class is liraglutide monotherapy in?
What development phase is liraglutide monotherapy in?
What are the side effects of liraglutide monotherapy?
What does liraglutide monotherapy target?
Related
- Drug class: All GLP-1 receptor agonist drugs
- Target: All drugs targeting GLP-1R
- Manufacturer: The Fourth Affiliated Hospital of Zhejiang University School of Medicine — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes mellitus monotherapy
- Compare: liraglutide monotherapy vs similar drugs
- Pricing: liraglutide monotherapy cost, discount & access